I appreciate that, but I think there was an animal study only at that point and it was not originally a part of DCVax-L, and I do not believe they adjusted the formula of DCVax-L, and there is no indication of a 4th drug in the combination trial. So I think the Daiichi drug is yet to be included in a human combination trial.
It is very promising, but I don’t believe it is yet part of any human trial with DCVax-L. Do you have anything more conclusive re the combination trial?
Oh, I see, you’re saying the next SPORE trial will include. Yes, I agree with that.
Market Data 
Markets 
AI
